• Opaleye Management Inc., a major shareholder, has significantly reduced its stake in Liquidia.
• The change in holdings focuses attention on large shareholder activity in NasdaqCM:LQDA.

Liquidia, traded as NasdaqCM:LQDA, is currently priced at $34.38, with a return of 121.4% over the past year and a very large gain over the past 5 years. The stock has also moved 14.6% over the past week and 9.5% year to date, while showing a 22.2% decline over the past month, highlighting how quickly sentiment around the name can shift.

In this context, Opaleye Management Inc.'s decision to cut its position may prompt you to reassess what is driving interest in Liquidia at current levels. Large shareholder moves are one input among many, so it can be helpful to weigh this development alongside your view of the company, its recent share price swings and your own risk tolerance.

Stay updated on the most important news stories for Liquidia by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Liquidia.

Opaleye Management’s decision to sell 180,000 Liquidia shares, an estimated US$5.12m trade, is a meaningful move because it comes from an investor that still has sizeable exposure. Even after trimming, Liquidia accounts for 11.21% of Opaleye’s reportable assets, so this looks more like position resizing than a full-scale exit. For you as a shareholder, the key question is whether this reflects a view on valuation after a strong 121.4% one year return, a shift in Opaleye’s portfolio construction, or a change in conviction ahead of Liquidia’s 2025 results and earnings call scheduled for 5 March 2026. Large block sales can add short term pressure to trading and sentiment, especially in a biopharma name where expectations around products like YUTREPIA and L606 already carry execution risk. At the same time, ownership is still concentrated in a holder that knows the story well, which can signal that the long term thesis has not been abandoned, even if risk is being dialed back at current prices.

How This Fits Into The Liquidia Narrative

• The trim follows a period of strong share price performance and growing attention on YUTREPIA and the pipeline, which lines up with the narrative that early commercial traction and improving payer access have increased investor interest.
• It also highlights a possible challenge to the catalyst of scaling manufacturing capacity and pipeline progress, as a key holder is taking money off the table while the company is still investing heavily for future demand.
• The narrative focuses on product uptake, payer coverage and capacity expansion, but does not fully factor in how concentrated institutional holders, such as Opaleye, can influence trading liquidity and short term pricing when they rebalance.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Liquidia to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ A large shareholder reducing its stake can weigh on near term sentiment and contribute to volatility around key events like the upcoming 2025 earnings release.
• ⚠️ If Opaleye continues to sell, the overhang from additional supply could make it harder for the share price to respond cleanly to company specific news, regardless of fundamentals.
• 🎁 Despite the trim, Opaleye still has meaningful exposure, which suggests continued interest in Liquidia’s pulmonary hypertension focus and product portfolio.
• 🎁 Analysts highlight potential rewards around prescription growth and pipeline progress, and Liquidia has been flagged for strong earnings growth expectations and for trading well below one estimate of fair value.

What To Watch Going Forward

From here, it is worth tracking whether Opaleye’s filing is a one off rebalance or the start of a longer selling pattern, and how other institutional holders respond. The upcoming 2025 results and earnings call on 5 March 2026 will be a key checkpoint for updated commentary on YUTREPIA uptake, payer coverage and progress on L606, which may influence how investors interpret this stake reduction. Keeping an eye on trading volumes, short interest and any new ownership disclosures can help you gauge how the shareholder base is evolving relative to the company’s execution on its pulmonary arterial hypertension strategy.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Liquidia, head to the community page for Liquidia to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.